Madrigal Pharmaceuticals, Inc.

- The call transcript does not mention any current or planned fundraising activities through debt or equity. - Madrigal ended Q1 2026 with a strong cash position of approximately $818 million, down from $989 million at the end of 2025, reflecting quarter-specific uses such as upfront business development payments and API purchases. - The company states it is "well resourced" to support ongoing launch and pipeline advancement, implying no immediate need for external financing. - There is no discussion or indication of upcoming capital raises or debt offerings in the earnings call.

- The company has made strategic business development investments, including a $54.3 million onetime upfront expense in Q1 2026, and a $25 million upfront payment expected in Q2 2026 for the acquisition of ARO-PNPLA3. - They are investing in expanding their pipeline with more than 10 programs, including combination therapies anchored by Rezdiffra and siRNA assets. - Capital expenditures include timing of API (Active Pharmaceutical Ingredient) purchases to support future manufacturing of Rezdiffra. - They emphasize capital-efficient pipeline building, having assembled a leading NASH pipeline for less than $300 million. - Future investments focus on clinical trials, business development, commercial efforts including sales force expansion, and marketing campaigns to support long-term growth. - The company is preparing for profitability beyond 2026 while continuing to invest strategically in R&D and commercialization.

- The company expects steady patient additions and robust net sales growth through 2026, with Q2 off to a strong start (Page 4, 5, 6). - Rezdiffra sales reached over $1.1 billion in the last 12 months, signaling strong commercial momentum (Page 4). - Market expansion is significant, with addressable patients growing nearly 50% in 2 years—diagnosis rates and treatment penetration are increasing (Page 7). - The company anticipates the NASH market to expand for years, driven by low current diagnosis and treatment rates plus more companies entering the space (Page 12). - Combination use with GLP-1 therapies (background treatment in ~25% of patients) is expected to rise, potentially boosting efficacy and sales (Page 8, 12). - Long-term, the path to "mega blockbuster" sales growth depends on continuing to add patients, expand diagnosis, and build on the current therapy with combination regimens (Page 12, 13). - The firm is also investing in pipeline expansion to solidify future leadership and revenue streams (Page 13).

- Madrigal expects profitability to be inevitable beyond 2026, with preparation underway for that milestone. (Page 8) - The company is not planning to be profitable in 2026, specifically noting Q2 2026 losses due to the PNPLA3 acquisition and other factors. (Page 8) - Some quarters in 2026 might show brief profitability, but overall profitability is expected beyond the year. (Page 8) - The focus remains on supporting top-line growth through steady patient additions and commercial investment. (Pages 4, 6) - Full-year 2026 SG&A expenses are expected to increase due to expanded commercial efforts including endocrinology sales force expansion. (Page 4) - Operating expenses include onetime upfront business development expenses, impacting near-term losses. (Page 4) - The optimistic outlook is supported by blockbuster sales exceeding $1.1 billion on a 12-month basis and expanding market opportunity. (Pages 1, 4)

- The company currently has about 10 pipeline assets in development, primarily focused on NASH (nonalcoholic steatohepatitis). - They are looking for potential add-ons to the pipeline but are selective, focusing on mechanistic-driven opportunities and transactable assets. - Their pipeline expansion has been achieved for less than $300 million, considered very capital-efficient. - The company aims to round out the pipeline by adding mechanisms that complement their foundational therapy, Rezdiffra. - Their strategy is to advance these assets into the clinic, generate data, and make go/no-go decisions based on clinical progress. - They continue to monitor opportunities for business development but maintain discipline in capital allocation. - No specific pending orders or deals detailed beyond the mentioned ongoing pipeline development and recent BD activity.